Zainab M. Elsayed

33516, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Design and synthesis of 1,3,4-oxadiazole-tethered N-substituted isatin hybrids as SARS-CoV-2 main protease inhibitors: biological evaluation, kinetic investigation, and in silico studies.

Design and synthesis of 1,3,4-oxadiazole-tethered N-substituted isatin hybrids as SARS-CoV-2 main protease inhibitors: biological evaluation, kinetic investigation, and in silico studies.

Journal: RSC advances

Published: July 04, 2026

Targeting CDK-2 With Novel Indole-Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies.

Targeting CDK-2 With Novel Indole-Pyrazole Hybrids: Discovery of Potent Anticancer Agents Supported by Mechanistic and In Silico Studies.

Journal: Drug development research

Published: June 14, 2026

Correction: Discovery of potent bisindole-based pyrazolopyridine derivatives as topoisomerase inhibitors: DNA damage induction and synergistic antileukemic activity.

Correction: Discovery of potent bisindole-based pyrazolopyridine derivatives as topoisomerase inhibitors: DNA damage induction and synergistic antileukemic activity.

Journal: Frontiers in pharmacology

Published: May 30, 2026

Design and Synthesis of Indole-Based Imidazo[1,2-a]pyridine Derivatives as Antiseizure Candidates: Evaluation in Chemically Induced Seizure Models and In Vitro Antioxidant Assays.

Design and Synthesis of Indole-Based Imidazo[1,2-a]pyridine Derivatives as Antiseizure Candidates: Evaluation in Chemically Induced Seizure Models and In Vitro Antioxidant Assays.

Journal: ACS chemical neuroscience

Published: May 15, 2026

Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors.

Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors.

Journal: RSC medicinal chemistry

Published: March 04, 2026

Isatin-triazole/imidazole hybrids as dual CDK2/VEGFR2 inhibitors with potent anti-cancer activity: design, synthesis, and biological evaluations.

Isatin-triazole/imidazole hybrids as dual CDK2/VEGFR2 inhibitors with potent anti-cancer activity: design, synthesis, and biological evaluations.

Journal: Bioorganic chemistry

Published: December 11, 2025

Discovery of enaminone-linked benzofuran derivatives as dual VEGFR-2/hCA IX inhibitors exhibiting hypoxia-mediated chemosensitization.

Discovery of enaminone-linked benzofuran derivatives as dual VEGFR-2/hCA IX inhibitors exhibiting hypoxia-mediated chemosensitization.

Journal: RSC medicinal chemistry

Published: November 21, 2025

Discovery of Novel Piperidinyl-Based Benzoxazole Derivatives as Anticancer Agents Targeting VEGFR-2 and c-Met Kinases.

Discovery of Novel Piperidinyl-Based Benzoxazole Derivatives as Anticancer Agents Targeting VEGFR-2 and c-Met Kinases.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 19, 2025

In silico pipeline for GSK 3β inhibitor discovery in Alzheimer's disease using pharmacophore screening, docking, ADME filtering, and MD validation.

In silico pipeline for GSK 3β inhibitor discovery in Alzheimer's disease using pharmacophore screening, docking, ADME filtering, and MD validation.

Journal: Scientific reports

Published: November 19, 2025

Discovery of potent bisindole-based pyrazolopyridine derivatives as topoisomerase inhibitors: DNA damage induction and synergistic antileukemic activity.

Discovery of potent bisindole-based pyrazolopyridine derivatives as topoisomerase inhibitors: DNA damage induction and synergistic antileukemic activity.

Journal: Frontiers in pharmacology

Published: November 12, 2025

Development of New Pyrazolo [3,4-b]Pyridine Derivatives as Potent Anti-Leukemic Agents and Topoisomerase IIα Inhibitors with Broad-Spectrum Cytotoxicity.

Development of New Pyrazolo [3,4-b]Pyridine Derivatives as Potent Anti-Leukemic Agents and Topoisomerase IIα Inhibitors with Broad-Spectrum Cytotoxicity.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: October 16, 2025

Synthesis and Biological Evaluation of Imidazopyridine-Isatin Hybrids as Inhibitors of Leishmania major Growth.

Synthesis and Biological Evaluation of Imidazopyridine-Isatin Hybrids as Inhibitors of Leishmania major Growth.

Journal: Drug design, development and therapy

Published: September 27, 2025

Showing 1-12 of 45

Last Updated: 09/26/2026